We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Fluorescent Lymphocytes and Smudge Cells Explored in Infectious Mononucleosis

By LabMedica International staff writers
Posted on 30 Aug 2021
Print article
Image: The Sysmex DI-60 is an automated, cell-locating image analysis system. It is connected directly to the analyzer track and therefore eliminates the need for manual intervention in the hematology workflow in the imaging cycle (Photo courtesy of Sysmex Corporation)
Image: The Sysmex DI-60 is an automated, cell-locating image analysis system. It is connected directly to the analyzer track and therefore eliminates the need for manual intervention in the hematology workflow in the imaging cycle (Photo courtesy of Sysmex Corporation)
Infectious mononucleosis (also known as Glandular fever) is an infection most commonly caused by the Epstein-Barr virus (EBV), which is a human herpes virus. Glandular fever is not particularly contagious. It is spread mainly through contact with saliva, such as through kissing, or sharing food and drink utensils.

The mono test is 71% to 90% accurate and may be used as an initial test for diagnosing infectious mononucleosis (IM). However, the test does have a 25% false-negative rate due to the fact that some people infected with EBV do not produce the heterophile antibodies that the mono test is designed to detect. Atypical lymphocytes appear, but the heterophilic agglutination test is negative.

Clinical Laboratorians at the Peking University Third Hospital (Beijing, China) enrolled in a study 62 IM patients, 67 healthy controls, 84 patients with upper respiratory tract virus infection, and 35 patients with malignant lymphoid diseases, to explore the diagnostic value of high fluorescent lymphocytes (HFLC) and smudge cells for infectious mononucleosis (IM). The complete blood counts and leukocyte differential counts were tested, and the smudge cells were manually counted.

Complete blood counts including red blood cells (RBC), hemoglobin (HGB), white blood cells (WBC), and leukocyte differential count, platelet (PLT), and HFLC percentage (HFLC%) were investigated with the Sysmex XN 9000 (Sysmex Corporation, Kobe, Japan). Manual leukocyte classification and smudge cells were counted by Sysmex DI-60. A total of 200 nucleated cells were read on each slide. The number of smudge cells seen per 100 nucleated cells was counted, and the blood smears were observed by two experienced technicians under an optical microscope.

The investigators reported that the value of HFLC% and smudge cells of the IM group were significantly higher than those of healthy controls and disease controls, and the HFLC% value of IM patients was positively correlated with the number of reactive lymphocytes. When the cutoff value of HFLC% was 0.4%, and of IM was high (AUC = 0.995). When the smudge cells >2/100 nucleated cells, the diagnostic value was further enhanced (AUC = 1.000). When the cutoff value of the HFLC% was 1.2%, it effectively distinguished IM patients from upper respiratory tract virus infection patients (AUC = 0.934). When smudge cells >16/100 nucleated cells, it also has high differential diagnosis value (AUC = 0.913). The combination HFLC% and smudge cells for the differential diagnosis can be increased to 0.968.

The authors concluded that HFLC% and smudge cells can be used as effective indicators in the early diagnosis and differential diagnosis of IM. HFLC% assists the diagnosis of IM with the following advantages: first, this indicator has high specificity and sensitivity for the diagnosis of IM, which can effectively avoid missed diagnosed; second, HFLC%, as one of the blood routine indicators, can be obtained directly from the automatic blood analyzer. The study was published on August 17, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Peking University Third Hospital
Sysmex Corporation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.